In brief: Narhex, Norwood Abbey, Anadis, Phylogica
Thursday, 02 February, 2006
Narhex Life Sciences (ASX:NLS) has signed a manufacturing contract with Indian, Nasdaq-listed company Dr Reddy's for initial GMP-grade production of the prodrug of Narhex's candidate HIV protease inhibitor, DG35.
Norwood Abbey (ASX:NAL) has begun animal studies for the application of its needle-free injection device for the delivery of a drug to treat arthritis at Massachusetts Institute of Technology (MIT). The MIT studies will also extend to a range of other applications involving delivery of drugs into joints.
Anadis (ASX:ANX) is to chase opportunities in the international market of high-profile sporting organisations, including athletes preparing for competition in the Beijing Olympics in 2008, following the successful analysis that its over-the-counter travellers' diarrhoea product Travelan does not contain any prohibited substances.
Phylogica (ASX:PYC) has secured a European patent for a new high-level drug-screening technique for isolating Phylomer and other drug candidates that block protein interactions involved in disease. Phylogica is developing drugs based on phylomers -- short-chain, bioactive peptides derived from the highly specialised proteins of extremophile microbes.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
